RVMD Q3 2025 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$315M

Net Income

-$305M

EPS (Diluted)

$-1.61

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$207M

Free Cash Flow

-$211M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$655M

Stockholders' Equity

$1.6B

Cash & Equivalents

$217M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$315M	-$176M	-79.4%
Net Income	-$305M	-$156M	-95.3%